Objective: The aim of this study was to evaluate the cochlear micromechanics and central auditory function in patients with type 1 diabetes mellitus and to identify the site of possible dysfunction. Methods: Cochlear activity was evaluated by recording distortion product otoacoustic emissions (DPOAEs). DPOAEs were performed using an ILO 92 Otodynamics Analyser. Functional changes in the retrocochlear auditory pathway were evaluated by auditory brainstem responses (ABRs). DPOAEs and ABRs were measured in 42 normally hearing patients with type 1 diabetes mellitus aged 21 to 42 years, and 33 age-and sexmatched nondiabetic control subjects. Results: Both of the groups (diabetic and control) had normal and undifferentiated results in tonal and impedance audiometry. ABR peripheral transmission time (wave I) and central transmission time (interpeak latencies I-V) were significantly delayed in the diabetic compared with normal subjects, and the mean amplitudes of various DPOAEs were significantly reduced in the diabetic patients compared with the control subjects. Conclusions: Combined use of different procedures for monitoring central and peripheral portions of the auditory pathway in diabetic patients showed alterations in cochlear micromechanics and the retrocochlear auditory pathway. Hearing impairment in diabetic patients is usually mild and subclinical, and can be detected early by accurate and objective audiometric methods.
Diabetes mellitus is a chronic disorder of carbohydrate metabolism that results from relative or absolute insulin deficiency. In addition to severe metabolic disturbances, widespread pathologic changes in the human body have been observed. The relationship between diabetes mellitus and hearing impairment remains controversial. According to published surveys, the frequency of sensorineural hearing impairment ranges from 0% to 80%. Also, the correlation between hearing loss and the degree of chronic diabetic complications has yet to be confirmed. The typical hearing loss is described as a progressive, bilateral, sensorineural deafness of gradual onset that affects predominantly the higher frequencies (1) (2) (3) (4) . However, not all authors agree that diabetes mellitus can lead to a sensorineural hearing impairment (4) (5) (6) (7) .
The hearing loss associated with diabetes mellitus may be a result of localized microangiopathy in the inner ear, neuronal degeneration, or diabetic encephalopathy, but might also be due to derangement in the metabolism of glucose and the mechanism associated with hyperactivity of free oxygen radicals. These pathologic changes and metabolic disturbances might result in a cochlear, retrocochlear, or combined cochlear-retrocochlear hearing disorder.
The aim of this study was to examine the relationship between diabetes and hearing loss and, if any was found, to see if it was cochlear or retrocochlear, and to assess a possible relationship between hearing impairment and chronic diabetic complications (retinopathy and nephropathy).
Conventional audiometric tests are not sensitive enough to detect the initial phases of sensory loss, nor are they capable of determining the site and pattern of this hearing loss, so the current investigations were performed by auditory electrophysiologic procedures and otoacoustic emissions.
MATERIALS AND METHODS
The patient group included 42 normally hearing patients with type 1 diabetes between 21 and 42 years of age (mean age, 33 years). Patients were divided into two subgroups: group A com-prised diabetics without microangiopathy, and group B included diabetics with microangiopathy. General characteristics of the diabetic group are listed in Table 1 .
Microangiopathy was evaluated by ophthalmoscopy and 24-hour albumin excretion rate into urine. Clinical examinations were performed by the same otologist and internist. Metabolic control was determined by fasting blood glucose.
Subjects with a past history of ear disease, exposure to noise, ototoxic drugs, head or ear trauma, or a family history of deafness were excluded from the study.
The control group (healthy subjects without hearing and vestibular impairment) consisted of 33 age-and sex-matched subjects, with a mean age 31.7 years.
All subjects underwent an ear, nose, and throat examination and than had pure-tone audiograms performed, using a GSI-16 audiometer (Lucas Grason-Stadler, Littleton, MA, USA). Stapedial reflex decay tests were performed with a Grayson Staedler GSI-33.
The presence of hearing loss in the control and diabetic subjects assessed by abnormal audiometric and impedance audiometry tests was a criterion for exclusion from the study.
Auditory brainstem responses (ABRs) were recorded with an EP-Test system. The ABR measurements were performed in a sound-treated room using 2000 clicks of alternating polarity and 0.1-millisecond duration. Potentials were evoked by 80-dB hearing level (HL) clicks, presented monaurally at a rate of 31 per second. The band-pass filters were set at 200 to 2000 Hz. The latency of each peak and the interpeak latency were measured.
Distortion product otoacoustic emissions (DPOAEs) were recorded using an ILO 92 analyser (Otodynamics, Ltd., Herts, U.K.). DPOAE signals were evaluated as a function of stimulus intensity (input-output [I/O] function). Two primary pure tones at frequencies f1 and f2 were used in the test procedure. The level and the frequency ratio of the primaries were kept constant (L1 ‫ס‬ L2, f2/f1 ‫ס‬ 1.22). The levels were increased in 5-dB steps from 35 to 70 dB sound pressure level (SPL). The I/O function was evaluated at f2 ranging from 1000 to 6000 Hz. The criterion level was an I/O response two standard deviations (SD) above the mean value of the noise floor.
All statistical analyses were performed using Statistica software. Results are presented as means ±SD. Statistical evaluation was carried out by Student t test for unpaired data and nonparametric Mann-Whitney test. The level of significance was chosen at p < 0.05. Correlations were calculated with Spearman and Pearson correlation tests.
RESULTS

Tonal and impedance audiometry
Both groups (diabetic and control) had normal and undifferentiated results in tonal and impedance audiometry.
Auditory brainstem responses
In general, ABR morphology was normal in all the groups. Latencies for waves I, III, and V and interpeak latencies I to V were significantly longer in the diabetic patients than in the control group. Table 2A shows the mean ABR results in the control and diabetic subjects.
Relationship between auditory brainstem responses
and diabetic microangiopathy Our results showed no significant differences between the mean ABR latencies in the two groups of diabetic patients, those with microangiopathy and those without microangiopathy (Table 2B ). In addition, no correlations were observed between microvascular complications, peripheral transmission time (wave I), and brainstem conduction parameters in diabetic patients.
Distortion product otoacoustic emissions
The mean DPOAE amplitudes were significantly reduced in the diabetic group compared with the control subjects. Reduced mean DPOAE amplitudes in diabetic patients were found in the region of middle and high frequencies, from f2 ‫ס‬ 1000 to f2 ‫ס‬ 6000 Hz (p < 0.05). Mean results are presented in Table 3 .
Relationship between distortion product otoacoustic emissions and diabetic microangiopathy Although the mean DPOAE amplitudes in patients with microangiopathy were found to be more reduced than the mean DPOAE in patients without microangiopathy, in general no significant differences between the two diabetic groups were found (Table 4 ). In addition, no correlations were observed between diabetic microangiopathy and DPOAE amplitude reduction.
DISCUSSION
The relationship between diabetes mellitus and hearing impairment has been studied for more than a century, and is still a matter of controversy. Conventional audiometric tests are not sensitive enough to detect the initial phases of sensory loss, nor are they capable of determining the site and pattern of this hearing loss. In our study, however, the combined use of different procedures for (13), and reduction of the outer hair cells (11, 14) . All of these factors could alter the cochlear mechanics and consequently otoacoustic emissions (OAEs). Our results indicate the existence of alterations in the cochlear Another explanation for the lack of significant correlation between diabetic microangiopathy and OAE amplitude reduction could be the rich vascularization and numerous anastomoses in the cochlea (1, 2) . Because the cochlea has numerous alternative capillary pathways for the maintenance of adequate circulation, a patchy distribution of diabetic vascular alterations need not lead to marked changes. Strauss et al. claim that hearing impairment is caused only by gross vascular changes, and not by microangiopathy (15) . Another argument in support of the lack of significant correlation between diabetic retinopathy or nephropathy and inner ear dysfunction is the fact that only long-lasting diabetes causes degenerative changes in capillaries and small vessels of the whole body. It may therefore be suspected that microvascular changes in the inner ear are not directly dependent on the degree of microvascular complications in the retina or kidneys.
The results of our study showed that the retrocochlear auditory pathway in diabetic patients is also affected by their disease. Wave I latency and the I to V interpeak latency were significantly longer in the diabetic patients than in control subjects. These findings indicate peripheral and central disturbances in the auditory pathway. Moreover, in our diabetic group, no relationship between ABR latencies and microvascular complications (e.g., retinopathy and nephropathy) were found. This is in accordance with most previous studies (4, 6, 9, 16, 17) and can be explained by the fact that retinopathy and nephropathy often represent very late complications, whereas ABR impairment is found early in diabetes. In contrast to our study, Virtaniemi et al. (18) and Goldsher et al. (19) observed a positive correlation between ABR latencies and microvascular complications. These diverging results could be explained by the wide range of studied populations, and by use of different criteria for selection of control and diabetic subjects.
The observed delay in the neural conduction process may be related to the degeneration of central nervous system structures, which was described by ReskeNielsen et al. as diabetic encephalopathy (20) . Many investigators showed that diabetes leads to diffuse degenerative changes in the brain tissue, demyelination of ganglion cells, and multiple infarctions in neural tissue (20, 21) . Jorgensen and Buch (22) , Kovar (12) , and Makishima and Tanaka (11) observed thickening of the vessel walls of the vasa nervorum and demyelination in the acoustic nerve. Another explanation for altered central neural transmission may be an impairment in the electroconductive properties of the myelin sheath evoked by the various metabolic changes caused by diabetes (23) .
CONCLUSION
The combined use of different procedures for monitoring the central and peripheral portions of the auditory pathway in diabetic patients showed the existence of alterations in cochlear micromechanics and the retrocochlear auditory pathway. Compared with alterations in the central auditory pathway, the impairment of cochlear receptor function is relatively subtle in diabetes. The cochlea therefore seems less prone to damage than brain tissue. This may be because at the capillary level, brain tissue is more susceptible to anoxia resulting from diabetic angiopathy than the cochlea (1).
Hearing impairment in diabetic patients is in general mild and subclinical and can be detected early by accurate and objective audiometric methods. DPOAEs and ABRs seem to be able to detect the earliest cochlear and retrocochlear dysfunction in patients with type 1 diabetes mellitus.
